{"id":20768,"date":"2023-01-13T17:13:44","date_gmt":"2023-01-13T11:43:44","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20768"},"modified":"2023-05-22T12:12:59","modified_gmt":"2023-05-22T06:42:59","slug":"behcets-syndrome-treatment-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market","title":{"rendered":"Off-label Therapies Dominating the Behcet\u2019s Syndrome Treatment Market"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f451c633f91\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f451c633f91\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\/#The_apex_of_the_Behcets_syndrome_treatment_landscape\" >The apex of the Behcet\u2019s syndrome treatment landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\/#Low_diagnosis_lower_patients_lowest_development_in_Behcets_syndrome_treatment_landscape\" >Low diagnosis, lower patients, lowest development in Behcet\u2019s syndrome treatment landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\/#Key_developments_in_the_Behcets_syndrome_treatment_space_so_far\" >Key developments in the Behcet\u2019s syndrome treatment space so far<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\/#Expected_roadblocks_in_the_Behcets_syndrome_treatment_market\" >Expected roadblocks in the Behcet\u2019s syndrome treatment market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\/#The_optimistic_future_of_the_Behcets_syndrome_treatment_market\" >The optimistic future of the Behcet\u2019s syndrome treatment market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Behcet\u2019s syndrome is an uncommon multisystem inflammatory ailment marked by ulcers in the mouth and genitalia, different skin lesions, and eye abnormalities. It is linked to several new clinical symptoms, all caused by an underlying vasculitis that affects arteries of all diameters.<\/p>\n\n\n\n<p>The<strong> <\/strong><strong><em>HLA-B<\/em><\/strong><strong><em><sup>*<\/sup><\/em><\/strong><strong><em>5101<\/em><\/strong><strong> allele of <\/strong><strong><em>HLA-B51<\/em><\/strong> and other non-HLA genes are linked to Behcet\u2019s syndrome. Patients from these regions have more comparable clinical characteristics than patients from the west, whose condition has a weaker connection with HLA antigens. Although familial Behcet\u2019s syndrome is rare and has a clear pattern of inheritance, 15% of affected children have the familial condition.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>As per the DelveInsight assessment, in 2021, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-epidemiology-forecast\">diagnosed prevalent cases of Behcet\u2019s syndrome<\/a> was more than 69K in the 7MM. The highest number of cases was seen in Japan.<\/strong>&nbsp;<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-apex-of-the-behcet-s-syndrome-treatment-landscape\"><span class=\"ez-toc-section\" id=\"The_apex_of_the_Behcets_syndrome_treatment_landscape\"><\/span><strong>The apex of the Behcet\u2019s syndrome treatment landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-market\">Behcet\u2019s syndrome treatment market<\/a> was valued at around <strong>USD 94<\/strong> million in 2019 and is expected to reach <strong>USD 270 <\/strong>million by 2032, growing at a CAGR of <strong>~10% <\/strong>during the study period.&nbsp;<\/p>\n\n\n\n<p>Owing to the rarity of the disease, the choice of Behcet\u2019s syndrome treatment depends on the physician. Currently, off-label therapies sit at the top of Behcet\u2019s syndrome treatment landscape. Agents like <strong>colchicine, corticosteroids, azathioprine, anakinra, canakinumab, secukinumab, and ustekinumab<\/strong> are looked upon to manage Behcet\u2019s syndrome.<\/p>\n\n\n\n<p>Corticosteroids are used to treat inflammation, azathioprine is recommended in patients with recurrent arthritis, and glucocorticoids are considered during acute exacerbations. <a href=\"https:\/\/www.delveinsight.com\/report-store\/otezla-api-insights\"><strong>OTEZLA<\/strong><\/a><strong> <\/strong>is the first US FDA-approved Behcet\u2019s syndrome therapy to treat oral ulcers associated with Behcet\u2019s syndrome. <a href=\"https:\/\/www.delveinsight.com\/report-store\/infliximab-biosimilars-insight\"><strong>REMICADE (infliximab)<\/strong><\/a><strong> and <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/adalimumab-biosimilars-insight\"><strong>HUMIRA (adalimumab)<\/strong><\/a> are incorporated to treat refractory uveoretinitis in Behcet\u2019s and intestinal Behcet\u2019s disease.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The current Behcet\u2019s syndrome treatment landscape presents an unmet need for approved therapies for treating Behcet\u2019s syndrome.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Low_diagnosis_lower_patients_lowest_development_in_Behcets_syndrome_treatment_landscape\"><\/span><strong>Low diagnosis, lower patients, lowest development in Behcet\u2019s syndrome treatment landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Early Behcet\u2019s syndrome diagnosis continues to be extremely difficult without a reliable biological marker and an exact diagnostic test. Due to the insufficient scientific evidence and few cases reported leading to no prospective <a href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-pipeline-insight\">Behcet\u2019s syndrome clinical trials<\/a>, it presents a hurdle in developing new treatment modalities. Access to medicines that can effectively treat specific illness presentations remains a key barrier due to the lack of sizable randomized controlled clinical studies to examine the impact of various interventions in Behcet\u2019s syndrome.<\/p>\n\n\n\n<p>Behcet\u2019s syndrome treatment procedures for the vascular, neurologic, and gastrointestinal association are mostly founded on uncontrolled investigations. In this manner, future RCTs and multicenter observational examinations in these fields must further develop proof levels for treatment proposals in these areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_developments_in_the_Behcets_syndrome_treatment_space_so_far\"><\/span><strong>Key developments in the Behcet\u2019s syndrome treatment space so far<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>February 2020,<\/strong> the EMA granted MAA to <strong>OTEZLA <\/strong>to treat adult patients with oral ulcers associated with Behcet\u2019s syndrome who are candidates for systemic therapies.<\/li>\n\n\n\n<li>In <strong>September 2019,<\/strong> the PMDA granted approval for <strong>OTEZLA <\/strong>to treat oral ulcers associated with Behcet\u2019s syndrome in patients who have not responded sufficiently to local treatment.<\/li>\n\n\n\n<li>In <strong>July 2019,<\/strong> <strong>Amgen <\/strong>announced that the US FDA approved <strong>OTEZLA (apremilast) 30 mg<\/strong> BID for treating adult patients with oral ulcers associated with Behcet\u2019s syndrome.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Expected_roadblocks_in_the_Behcets_syndrome_treatment_market\"><\/span><strong>Expected roadblocks in the Behcet\u2019s syndrome treatment market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The lack of specific diagnostic approaches, such as laboratory tests, biomarkers, and updated diagnostic criteria that account for the neurological, GI, and vascular complications associated with Behcet\u2019s syndrome, leaves clinicians in a bind. Moreover, there are no specific consensus-driven recommendations for all manifestations of Behcet\u2019s syndrome that take gender or age into account, as age and early disease can influence the treatment of complications associated with Behcet\u2019s syndrome.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-1024x263.png\" alt=\"Behcet\u2019s Syndrome Market Outlook\" class=\"wp-image-20801\" width=\"1024\" height=\"263\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-1024x263.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-300x77.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-150x39.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-768x197.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-1536x394.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-2048x526.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/18120912\/Behcets-Syndrome-Market-Outlook-1-1568x402.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"><strong>Behcet\u2019s Syndrome Market Assessment<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Although the discovery of TNF inhibitors\u2019 role in Behcet\u2019s syndrome opened up <a href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-market\">new opportunities in Behcet\u2019s syndrome treatment market<\/a>, the reluctance of patients and physicians to begin new biologics due to safety concerns is a major setback for biologics. According to research, even though approximately<strong> 60%<\/strong> of patients achieve remission after the first few years, Behcet\u2019s syndrome is associated with high relapse rates, a poor prognosis, and mortality.<\/p>\n\n\n\n<p>Another impediment to researching potential new and existing therapies is a lack of understanding of Behcet\u2019s syndrome pathogenesis. While there is a large body of literature on the possible mechanisms of Behcet\u2019s syndrome, understanding whether these are influenced by environmental, genetic, or other factors is still very limited. Due to the disease\u2019s complexity and multisystem involvement, a holistic approach to management with the involvement of specialists is required.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_optimistic_future_of_the_Behcets_syndrome_treatment_market\"><\/span><strong>The optimistic future of the Behcet\u2019s syndrome treatment market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As Behcet\u2019s syndrome demands more advancements to bridge the gap between research and Behcet\u2019s syndrome treatment, more interventional studies are required to understand the disease and establish treatment options. According to research articles, Behcet\u2019s syndrome is widespread along the old Silk Road, which extends from eastern Asia to the Mediterranean, but because of the migration of Turks to Germany and other European nations, it might encourage research into the condition.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook-1024x256.png\" alt=\"behcet's syndrome market outlook\" class=\"wp-image-20774\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164254\/behcets-syndrome-market-outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1673607215000\"><strong class=\"schema-faq-question\"><strong>1. What is Behcet\u2019s syndrome?<\/strong><\/strong> <p class=\"schema-faq-answer\">Behcet\u2019s syndrome is an uncommon multisystem inflammatory ailment marked by ulcers in the mouth and genitalia, different skin lesions, and eye abnormalities. It is linked to several new clinical symptoms, all caused by an underlying vasculitis that affects arteries of all diameters.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1673607241087\"><strong class=\"schema-faq-question\"><strong>2. What are Behcet\u2019s syndrome symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">The Behcet\u2019s syndrome symptoms include mucous membrane lesions of the mouth (canker sores) and genitals (ulcers), which disappear and reappear on their own. Individuals with Behcet\u2019s syndrome may also experience eye inflammation (anterior uveitis, posterior uveitis, or panuveitis).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1673607266621\"><strong class=\"schema-faq-question\"><strong>3. How to diagnose Behcet&#8217;s syndrome?<\/strong><\/strong> <p class=\"schema-faq-answer\">There are no specific tests or biomarkers that can confirm a Behcet\u2019s syndrome diagnosis. Clinical criteria, the occurrence of disease signs and symptoms, and positive clinical criteria are referred to as the International Study Group (ISG) criteria for Behcet\u2019s disease.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1673607283822\"><strong class=\"schema-faq-question\"><strong>4. What are the current Behcet\u2019s syndrome treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">The only therapy approved by US FDA is OTEZLA (apremilast) for treating oral ulcers associated with Behcet\u2019s syndrome. In Japan, REMICADE (infliximab) and HUMIRA (adalimumab) are approved for refractory uveoretinitis in Behcet\u2019s disease and intestinal Behcet\u2019s disease; however, several off-label therapies, such as colchicine, corticosteroids, azathioprine, anakinra, canakinumab, secukinumab, and ustekinumab, are used for the management of Behcet\u2019s syndrome.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Behcet\u2019s syndrome is an uncommon multisystem inflammatory ailment marked by ulcers in the mouth and genitalia, different skin lesions, and eye abnormalities. It is linked to several new clinical symptoms, all caused by an underlying vasculitis that affects arteries of all diameters. The HLA-B*5101 allele of HLA-B51 and other non-HLA genes are linked to Behcet\u2019s [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":20769,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":4,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20156,20168,20157,20158,900,17360,908],"industry":[17225],"therapeutic_areas":[17234],"class_list":["post-20768","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-behcets-syndrome","tag-behcets-syndrome-clinical-trials","tag-behcets-syndrome-treatment","tag-behcets-syndrome-treatment-market","tag-humira","tag-otezla","tag-remicade","industry-pharmaceutical","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rich Insights into the Behcet\u2019s Syndrome Treatment Market<\/title>\n<meta name=\"description\" content=\"Currently, off-label therapies sit at top of Behcet\u2019s syndrome treatment market. However, there is unmet need for approved therapies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rich Insights into the Behcet\u2019s Syndrome Treatment Market\" \/>\n<meta property=\"og:description\" content=\"Currently, off-label therapies sit at top of Behcet\u2019s syndrome treatment market. However, there is unmet need for approved therapies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-13T11:43:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-22T06:42:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164114\/behcets-syndrome-treatment-market.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rich Insights into the Behcet\u2019s Syndrome Treatment Market","description":"Currently, off-label therapies sit at top of Behcet\u2019s syndrome treatment market. However, there is unmet need for approved therapies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market","og_locale":"en_US","og_type":"article","og_title":"Rich Insights into the Behcet\u2019s Syndrome Treatment Market","og_description":"Currently, off-label therapies sit at top of Behcet\u2019s syndrome treatment market. However, there is unmet need for approved therapies","og_url":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-01-13T11:43:44+00:00","article_modified_time":"2023-05-22T06:42:59+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164114\/behcets-syndrome-treatment-market.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market","url":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market","name":"Rich Insights into the Behcet\u2019s Syndrome Treatment Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164114\/behcets-syndrome-treatment-market.png","datePublished":"2023-01-13T11:43:44+00:00","dateModified":"2023-05-22T06:42:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Currently, off-label therapies sit at top of Behcet\u2019s syndrome treatment market. However, there is unmet need for approved therapies","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607215000"},{"@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607241087"},{"@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607266621"},{"@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607283822"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164114\/behcets-syndrome-treatment-market.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164114\/behcets-syndrome-treatment-market.png","width":772,"height":482,"caption":"behcets-syndrome-treatment-market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607215000","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607215000","name":"1. What is Behcet\u2019s syndrome?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Behcet\u2019s syndrome is an uncommon multisystem inflammatory ailment marked by ulcers in the mouth and genitalia, different skin lesions, and eye abnormalities. It is linked to several new clinical symptoms, all caused by an underlying vasculitis that affects arteries of all diameters.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607241087","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607241087","name":"2. What are Behcet\u2019s syndrome symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The Behcet\u2019s syndrome symptoms include mucous membrane lesions of the mouth (canker sores) and genitals (ulcers), which disappear and reappear on their own. Individuals with Behcet\u2019s syndrome may also experience eye inflammation (anterior uveitis, posterior uveitis, or panuveitis).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607266621","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607266621","name":"3. How to diagnose Behcet's syndrome?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"There are no specific tests or biomarkers that can confirm a Behcet\u2019s syndrome diagnosis. Clinical criteria, the occurrence of disease signs and symptoms, and positive clinical criteria are referred to as the International Study Group (ISG) criteria for Behcet\u2019s disease.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607283822","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/behcets-syndrome-treatment-market#faq-question-1673607283822","name":"4. What are the current Behcet\u2019s syndrome treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The only therapy approved by US FDA is OTEZLA (apremilast) for treating oral ulcers associated with Behcet\u2019s syndrome. In Japan, REMICADE (infliximab) and HUMIRA (adalimumab) are approved for refractory uveoretinitis in Behcet\u2019s disease and intestinal Behcet\u2019s disease; however, several off-label therapies, such as colchicine, corticosteroids, azathioprine, anakinra, canakinumab, secukinumab, and ustekinumab, are used for the management of Behcet\u2019s syndrome.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/01\/13164114\/behcets-syndrome-treatment-market-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Behcet\u2019s syndrome clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Humira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Otezla<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Remicade<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome<\/span>","<span class=\"advgb-post-tax-term\">Behcet\u2019s syndrome clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment<\/span>","<span class=\"advgb-post-tax-term\">Behcet\u2019s Syndrome treatment market<\/span>","<span class=\"advgb-post-tax-term\">Humira<\/span>","<span class=\"advgb-post-tax-term\">Otezla<\/span>","<span class=\"advgb-post-tax-term\">Remicade<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 13, 2023","modified":"Updated on May 22, 2023"},"absolute_dates_time":{"created":"Posted on Jan 13, 2023 5:13 pm","modified":"Updated on May 22, 2023 12:12 pm"},"featured_img_caption":"behcets-syndrome-treatment-market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20768"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20768\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20769"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20768"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20768"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}